<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Gen Pract</journal-id><journal-id journal-id-type="iso-abbrev">Br J Gen Pract</journal-id><journal-id journal-id-type="publisher-id">bjgp</journal-id><journal-title-group><journal-title>The British Journal of General Practice</journal-title></journal-title-group><issn pub-type="ppub">0960-1643</issn><issn pub-type="epub">1478-5242</issn><publisher><publisher-name>Royal College of General Practitioners</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25267050</article-id><article-id pub-id-type="pmc">4173727</article-id><article-id pub-id-type="doi">10.3399/bjgp14X681817</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sheppard</surname><given-names>James P</given-names></name><degrees>PhD, MRC</degrees><role>Post-doctoral research fellow</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fletcher</surname><given-names>Kate</given-names></name><degrees>PhD</degrees><role>Research fellow</role></contrib><aff>Primary Care Clinical Sciences, University of Birmingham, Birmingham.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>McManus</surname><given-names>Richard J</given-names></name><degrees>MSc, PhD, DRCOG, FRCGP</degrees><role>NIHR professor</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mant</surname><given-names>Jonathan</given-names></name><degrees>MA, MSc, FFPH, MD</degrees><role>Professor</role></contrib><aff>Primary Care Unit, University of Cambridge, Cambridge.</aff></contrib-group><author-notes><corresp><bold>Address for correspondence</bold> Richard J McManus, Nuffield Department of Primary Care Health Sciences, NIHR School for Primary Care Research, University of Oxford, Oxford OX2 6GG. E-mail: <email>richard.mcmanus@phc.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>9</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>64</volume><issue>627</issue><fpage>e641</fpage><lpage>e648</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2014</year></date><date date-type="rev-request"><day>08</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; British Journal of General Practice 2014</copyright-statement><copyright-year>2014</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p><!--CREATIVE COMMONS-->This is an OpenAccess article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Treatment for uncomplicated stage 1 hypertension is recommended in most international guidelines but there is little evidence to indicate that therapy is beneficial.</p></sec><sec><title>Aim</title><p>To estimate the prevalence of this condition in an untreated population and the potential costs of initiating therapy in such patients.</p></sec><sec><title>Design and setting</title><p>Cross-sectional study of anonymised patient records in 19 general practices in the West Midlands, UK.</p></sec><sec><title>Method</title><p>Data relating to patient demographics, existing cardiovascular disease (CVD), and risk factors (blood pressure and cholesterol) were extracted from patient records. Patients with a blood pressure of 140/90&#x02013;159/99 mmHg, no CVD, and &#x0003c;20% 10-year cardiovascular risk were classified as having uncomplicated stage 1 hypertension. Missing data were imputed. The prevalence of untreated, uncomplicated stage 1 hypertension was estimated using descriptive statistics and extrapolated using national data. The cost of achieving blood pressure control in this population was examined in a cost&#x02013;impact analysis using published costs from previous studies.</p></sec><sec><title>Results</title><p>Of the 34 975 patients (aged 40&#x02013;74 years) in this study, untreated, uncomplicated stage 1 hypertension was present in 2867 individuals (8.2%, 95% confidence interval [CI] = 7.9 to 8.5). This is equivalent to 1 892 519 patients in England and Wales, for whom the additional cost of controlling blood pressure, according to guidelines, was estimated at &#x000a3;106&#x02013;229 million per annum, depending on the health professional delivering care.</p></sec><sec><title>Conclusion</title><p>Untreated, uncomplicated stage 1 hypertension is relatively common, affecting 1 in 12 patients aged 40&#x02013;74 years in primary care. Current international guidelines and pay-for-performance targets, if followed, will incur significant costs for a patient benefit that is debatable.</p></sec></abstract><kwd-group><kwd>antihypertensive agents</kwd><kwd>cardiovascular disease risk</kwd><kwd>guidelines</kwd><kwd>primary prevention</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Hypertension is a key risk factor for the development of cardiovascular disease (CVD),<xref rid="b1" ref-type="bibr">1</xref> the major cause of morbidity and mortality worldwide.<xref rid="b2" ref-type="bibr">2</xref> Classifications of hypertension are, by definition, arbitrary and, although most guidelines now include consideration of underlying CVD risk, many recommend pharmacological treatment of blood pressure when it is sustained at &#x02265;140/90 mmHg, regardless of the underlying risk, end organ damage, diabetes, or history of CVD (<xref ref-type="table" rid="table1">Table 1</xref>).<xref rid="b3" ref-type="bibr">3</xref>&#x02013;<xref rid="b13" ref-type="bibr">13</xref></p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><p>Summary of treatment recommendations for patients with stage 1, 2, and 3 hypertension</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" rowspan="3" align="left" colspan="1"><bold>Guideline</bold></th><th valign="bottom" rowspan="3" align="center" colspan="1"><bold>Country/region</bold></th><th valign="bottom" rowspan="3" align="center" colspan="1"><bold>Year</bold></th><th colspan="3" valign="bottom" align="center" rowspan="1"><bold>Low CVD risk</bold></th><th colspan="3" valign="bottom" align="center" rowspan="1"><bold>High CVD risk<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></bold></th><th valign="bottom" rowspan="3" align="left" colspan="1"><bold>Notes</bold></th></tr><tr><th colspan="3" valign="bottom" align="center" rowspan="1">
<hr/></th><th colspan="3" valign="bottom" align="center" rowspan="1">
<hr/></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 1 HT</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 2 HT</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3 HT</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 1 HT</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 2 HT</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3 HT</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">European Society of Hypertension<xref rid="b3" ref-type="bibr">3</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Europe</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Initiate therapy in low-risk stage 1 HT if lifestyle modification is unsuccessful</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Canadian Hypertension Education Program<xref rid="b4" ref-type="bibr">4</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Canada</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Therapy should only be initiated if mean BP is raised on three occasions (high risk or stage 2&#x02013;3 HT) or five occasions (stage 1 HT and low risk)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">National Institute for Health and Care Excellence<xref rid="b12" ref-type="bibr">12</xref></td><td valign="top" align="center" rowspan="1" colspan="1">UK</td><td valign="top" align="center" rowspan="1" colspan="1">2011</td><td valign="top" align="center" rowspan="1" colspan="1">Lifestyle advice</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Diagnosis of hypertension is based on a combination of clinic and ambulatory BP readings</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">National Heart Foundation of Australia<xref rid="b11" ref-type="bibr">11</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Australia</td><td valign="top" align="center" rowspan="1" colspan="1">2010</td><td valign="top" align="center" rowspan="1" colspan="1">Lifestyle advice</td><td valign="top" align="center" rowspan="1" colspan="1">Lifestyle advice</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment is also recommended in patients with moderate CVD risk (10&#x02013;15%) and raised BP (&#x0003e;140/90 mmHg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Latin American Society of Hypertension<xref rid="b7" ref-type="bibr">7</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Latin America</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Therapy should only be initiated in patients with stage 1 or 2 HT if raised BP persists for &#x02018;a few weeks&#x02019; (in those with moderate CVD risk) or &#x02018;several months&#x02019; (in those with low CVD risk)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Japanese Society of Hypertension<xref rid="b9" ref-type="bibr">9</xref></td><td valign="top" align="center" rowspan="1" colspan="1">Japan</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Therapy should be initiated in patients with stage 1 HT if raised BP is sustained after a period of lifestyle modification</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">American Heart Association<xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref>,<xref rid="b13" ref-type="bibr">13</xref></td><td valign="top" align="center" rowspan="1" colspan="1">US</td><td valign="top" align="center" rowspan="1" colspan="1">2006&#x02013;2014</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">JNC8 suggests patients aged &#x02265;60 years should only be treated if BP is &#x02265;150/90 mmHg</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">New Zealand Guidelines Group<xref rid="b10" ref-type="bibr">10</xref></td><td valign="top" align="center" rowspan="1" colspan="1">New Zealand</td><td valign="top" align="center" rowspan="1" colspan="1">2003</td><td valign="top" align="center" rowspan="1" colspan="1">Lifestyle advice</td><td valign="top" align="center" rowspan="1" colspan="1">Lifestyle advice</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment is based solely on CVD risk: those with high CVD risk should receive therapy. Stage 3 HT = &#x02265;170/100 mmHg</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WHO/International Society of Hypertension<xref rid="b8" ref-type="bibr">8</xref></td><td valign="top" align="center" rowspan="1" colspan="1">World</td><td valign="top" align="center" rowspan="1" colspan="1">2003</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="center" rowspan="1" colspan="1">Therapy</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1"><label>a</label><p>Includes estimated CVD risk &#x02265;20%, existing CVD, diabetes, renal disease, and target organ damage. Stage 1 hypertension = 140/90&#x02013;159/99 mmHg; stage 2 hypertension = 160/100&#x02013;179/109 mmHg; stage 3 hypertension = &#x02265;180/110 mmHg. BP = blood pressure. CVD = cardiovascular disease. HT = hypertension. JNC8 = Eighth Joint National Committee. WHO = World Health Organization.</p></fn></table-wrap-foot></table-wrap><p>The treatment of uncomplicated (that is, low risk of CVD) stage 1 hypertension (sustained blood pressure of 140/90&#x02013;159/99 mmHg) has long been considered controversial due to the paucity of evidence to support such a strategy.<xref rid="b14" ref-type="bibr">14</xref>&#x02013;<xref rid="b17" ref-type="bibr">17</xref> A recent Cochrane Review<xref rid="b18" ref-type="bibr">18</xref> examined 8912 patients from four clinical trials and found no significant reduction in mortality or cardiovascular events with treatment. Despite these data, new international guidelines and pay-for-performance indicators continue to recommend treatment.<xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b19" ref-type="bibr">19</xref> Only guidelines in the UK, Australia, and New Zealand recommend lifestyle advice rather than pharmacological interventions for uncomplicated stage 1 hypertension (<xref ref-type="table" rid="table1">Table 1</xref>).<xref rid="b10" ref-type="bibr">10</xref>&#x02013;<xref rid="b12" ref-type="bibr">12</xref></p><p>The impact of these recommendations on clinical practice is unclear. Although the prevalence of hypertension is well documented across the world,<xref rid="b20" ref-type="bibr">20</xref>&#x02013;<xref rid="b24" ref-type="bibr">24</xref> few studies have examined the prevalence of stage 1 hypertension<xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref> and none, to the authors&#x02019; knowledge, have examined its prevalence with regard to CVD risk. This study aimed to establish the total number of individuals potentially requiring treatment for uncomplicated stage 1 hypertension, according to international guidelines, in a typical UK primary care population. These estimates were extrapolated to national data<xref rid="b27" ref-type="bibr">27</xref> and the cost impact of achieving blood pressure control was quantified in this population using published costs.<xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b29" ref-type="bibr">29</xref></p></sec><sec sec-type="methods"><title>METHOD</title><sec sec-type="methods"><title>Data collection</title><p>A cross-sectional retrospective study of anonymised, primary care medical records was conducted in 19 general practices across the West Midlands, UK. The methods of data collection have been detailed elsewhere.<xref rid="b30" ref-type="bibr">30</xref>,<xref rid="b31" ref-type="bibr">31</xref> Briefly, relevant data were extracted from patient medical records using MIQUEST software. All data queries were run between 17 October 2008 and 6 October 2009; extracted data included:
<list list-type="bullet"><list-item><p>demographic information;</p></list-item><list-item><p>cardiovascular risk-factor details; and</p></list-item><list-item><p>all cholesterol and blood pressure lowering medication prescribed within the 90 days prior to the query date.</p></list-item></list></p><boxed-text position="float"><sec><title>How this fits in</title><p>There are varying recommendations on how to treat people with uncomplicated stage 1 hypertension, but many guidelines recommend therapy for all whose blood pressure is &#x02265;140/90 mmHg, despite the lack of robust clinical trial evidence supporting treatment. At least 1 in 12 patients aged 40&#x02013;74 years old have the condition but receive no treatment for it. The cost of initiating treatment in these individuals in England and Wales in line with current international guidelines, would be substantial (&#x000a3;106&#x02013;229 million: US$180&#x02013;389 million and &#x020ac;134&#x02013;289 million) in the first year, but the benefits for patients are unknown.</p></sec></boxed-text><p>This study focused on individuals aged 40&#x02013;74 years, as younger people require further assessment for secondary causes of hypertension before treatment is administered<xref rid="b12" ref-type="bibr">12</xref> and older individuals are likely to fall into the high CVD risk group and, therefore, not be relevant to the research questions addressed here.</p></sec><sec><title>Definition of uncomplicated stage 1 hypertension</title><p>This study aimed to establish the prevalence of untreated, uncomplicated stage 1 hypertension. As such, patients with no blood pressure reading from the preceding 5 years, those with existing CVD, or those already receiving blood pressure or cholesterol-lowering therapy were not considered in this analysis; it was assumed that patients receiving blood pressure- or cholesterol-lowering therapy had been at high risk of CVD prior to initiation.<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b32" ref-type="bibr">32</xref> The remaining patients formed a potential primary-prevention population and were subdivided on the basis of blood pressure level (&#x0003c;140/90 mmHg = normotension; 140/90&#x02013;159/99 mmHg = stage 1 hypertension; &#x02265;160/100 mmHg = stage 2&#x02013;3 hypertension) and CVD risk score.</p><p>Given that the classification of hypertension was based on only the most recent clinic blood pressure reading, the prevalence of stage 1 hypertension was adjusted to account for the 56% positive predictive value (PPV) of clinic blood pressure measurements around the diagnostic threshold for hypertension.<xref rid="b33" ref-type="bibr">33</xref> The prevalence of stage 2&#x02013;3 hypertension was not adjusted due to uncertainty about the PPV of blood pressure measurement at higher levels. No attempt was made to impute missing blood pressure data.</p></sec><sec><title>Definition of cardiovascular risk status</title><p>Where possible, data on cardiovascular risk factors were used to estimate CVD risk using the Framingham equation.<xref rid="b34" ref-type="bibr">34</xref> This risk calculator was recommended by the National Institute for Health and Care Excellence (NICE)<xref rid="b35" ref-type="bibr">35</xref> at the time of data collection; it is now recognised, however, that other risk calculators<xref rid="b36" ref-type="bibr">36</xref> may be more appropriate for use in UK populations.<xref rid="b32" ref-type="bibr">32</xref> CVD risk scores were adjusted by a factor of 1.4 or 1.5 for patients of South Asian origin or a family history of premature cardiovascular events respectively.<xref rid="b35" ref-type="bibr">35</xref> Where total or high-density lipoprotein (HDL) cholesterol information was not available, values were imputed using the observed mean cholesterol for patients of the same sex and age group (5-year age bands) with existing cholesterol readings. All other risk factors were assumed not to be present if they were absent from the patient medical records.</p></sec><sec><title>Estimation of costs</title><p>The potential costs of treating uncomplicated stage 1 hypertension were examined in a cost&#x02013;impact analysis using the methodology utilised by NICE for the development of costing tools to assist the implementation of new guidance.<xref rid="b37" ref-type="bibr">37</xref> This methodology uses data describing the affected population, the required activity, and the cost of that activity to estimate the financial impact of implementing new guidance on health service budgets. It does not consider these costs in the context of quality-adjusted life years gained, as is the case in a health economic analysis.</p><p>The level of new activity generated by guideline implementation was defined in the present study as the number of drugs required to control blood pressure to &#x0003c;140/90 mmHg in each patient and the health professional&#x02019;s time incurred when prescribing and monitoring the treatment regimen. These figures were estimated using data from the Hypertension Optimal Treatment trial.<xref rid="b38" ref-type="bibr">38</xref> Drug choice was guided by the NICE treatment algorithm, which recommends different combinations of therapy according to patient age and ethnic group.<xref rid="b12" ref-type="bibr">12</xref></p><p>The costs of resource utilisation were estimated using the <italic>NHS Electronic Drug Tariff</italic>
<xref rid="b28" ref-type="bibr">28</xref> (cost of drug prescription) and <italic>Unit Costs of Health and Social Care 2012</italic>
<xref rid="b29" ref-type="bibr">29</xref> (cost of service provision) (<xref ref-type="table" rid="table2">Table 2</xref>). This analysis focused on the short-term costs of guideline implementation (first year); it did not consider any possible cost savings resulting from future reductions in cardiovascular morbidity or mortality as it has been argued that such reductions would be minimal in this population.<xref rid="b18" ref-type="bibr">18</xref></p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><p>Unit costs of treatment and NHS service delivery required to achieve blood pressure control in patients with uncomplicated stage 1 hypertension</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="2" align="left" colspan="1"><bold>Cost type</bold></th><th valign="bottom" rowspan="2" align="center" colspan="1"><bold>Cost per unit, &#x000a3;</bold></th><th colspan="4" valign="bottom" align="center" rowspan="1"><bold>Annual cost per patient, &#x000a3;</bold>
<hr/></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Patients requiring no drugs</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Patients requiring one drug</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Patients requiring two different drugs</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Patients requiring three different drugs</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Drugs<xref ref-type="table-fn" rid="tfn2"><sup>a</sup></xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Amlodipine 10 mg (28-tablet pack)</td><td valign="top" align="center" rowspan="1" colspan="1">1.07 (1 pack)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">13.96</td><td valign="top" align="center" rowspan="1" colspan="1">27.92</td><td valign="top" align="center" rowspan="1" colspan="1">41.87</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Ramipril 10 mg (28-capsule pack)</td><td valign="top" align="center" rowspan="1" colspan="1">1.30 (1 pack)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">16.96</td><td valign="top" align="center" rowspan="1" colspan="1">33.92</td><td valign="top" align="center" rowspan="1" colspan="1">50.87</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Indapamide 2.5 mg (28-tablet pack)</td><td valign="top" align="center" rowspan="1" colspan="1">1.40 (1 pack)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">18.26</td><td valign="top" align="center" rowspan="1" colspan="1">36.53</td><td valign="top" align="center" rowspan="1" colspan="1">54.79</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Total treatment for a patient aged &#x0003c;55 years<xref ref-type="table-fn" rid="tfn3"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">16.96</td><td valign="top" align="center" rowspan="1" colspan="1">30.92</td><td valign="top" align="center" rowspan="1" colspan="1">49.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Total treatment for a patient aged &#x02265;55 years<xref ref-type="table-fn" rid="tfn3"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">13.96</td><td valign="top" align="center" rowspan="1" colspan="1">30.92</td><td valign="top" align="center" rowspan="1" colspan="1">49.18</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Service delivery<sup><xref ref-type="table-fn" rid="tfn4">c</xref>,<xref ref-type="table-fn" rid="tfn5">d</xref></sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Practice nurse</td><td valign="top" align="center" rowspan="1" colspan="1">45/hour</td><td valign="top" align="center" rowspan="1" colspan="1">11.25</td><td valign="top" align="center" rowspan="1" colspan="1">22.50</td><td valign="top" align="center" rowspan="1" colspan="1">33.75</td><td valign="top" align="center" rowspan="1" colspan="1">45.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Nurse specialist</td><td valign="top" align="center" rowspan="1" colspan="1">81/hour</td><td valign="top" align="center" rowspan="1" colspan="1">20.25</td><td valign="top" align="center" rowspan="1" colspan="1">40.50</td><td valign="top" align="center" rowspan="1" colspan="1">60.75</td><td valign="top" align="center" rowspan="1" colspan="1">81.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;GP</td><td valign="top" align="center" rowspan="1" colspan="1">185/hour</td><td valign="top" align="center" rowspan="1" colspan="1">36.00</td><td valign="top" align="center" rowspan="1" colspan="1">72.00</td><td valign="top" align="center" rowspan="1" colspan="1">108.00</td><td valign="top" align="center" rowspan="1" colspan="1">144.00</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Total cost of treatment (aged &#x02265;55 years)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Drug + practice nurse</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">11.25</td><td valign="top" align="center" rowspan="1" colspan="1">36.46</td><td valign="top" align="center" rowspan="1" colspan="1">64.67</td><td valign="top" align="center" rowspan="1" colspan="1">94.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Drug + nurse specialist</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">20.25</td><td valign="top" align="center" rowspan="1" colspan="1">54.46</td><td valign="top" align="center" rowspan="1" colspan="1">91.67</td><td valign="top" align="center" rowspan="1" colspan="1">130.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Drug + GP</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">36.00</td><td valign="top" align="center" rowspan="1" colspan="1">85.96</td><td valign="top" align="center" rowspan="1" colspan="1">138.92</td><td valign="top" align="center" rowspan="1" colspan="1">193.18</td></tr></tbody></table><table-wrap-foot><fn id="tfn2"><label>a</label><p><italic>Costs taken from</italic> NHS Electronic Drug Tariff <italic>database, correct as of May 2013.<xref rid="b28" ref-type="bibr">28</xref></italic></p></fn><fn id="tfn3"><label>b</label><p>As defined by the National Institute for Health and Care Excellence treatment algorithm.</p></fn><fn id="tfn4"><label>c</label><p>Costs of service delivery given per consultation (unless otherwise stated) based on a face-to-face, 15-minute nurse consultation or a 11.7-minute GP consultation.</p></fn><fn id="tfn5"><label>d</label><p><italic>Costs taken from</italic> Unit Costs of Health and Social Care 2012<italic>.<xref rid="b29" ref-type="bibr">29</xref></italic></p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="methods"><title>Analysis</title><p>Descriptive statistics were used to define the proportion of patients in each group with different levels of blood pressure control (normotension, stage 1, and stage 2&#x02013;3 hypertension). Data are presented according to age (40&#x02013;54 years and 55&#x02013;74 years) and sex; comparisons were made using &#x003c7;<sup>2</sup> tests.</p><p>The number of people with untreated, uncomplicated stage 1 hypertension in the population of England and Wales was estimated by extrapolating from the local prevalence estimates derived from this study to national population data.<xref rid="b27" ref-type="bibr">27</xref> All data are presented as a mean, &#x000b1; standard deviation (SD), and proportion of the total population with 95% confidence intervals (CIs) (unless otherwise stated). Costs were calculated in pounds sterling and converted to US dollars and euros for comparison purposes. All analyses were carried out using SPSS software (version 21).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec sec-type="intro"><title>Population characteristics</title><p>Of the 90 516 patients registered at participating practices, 34 975 were aged 40&#x02013;74 years and could have been included in this analysis; however, of these, 2550 (7.3%) patients had existing CVD, 7406 (21.2%) were already on treatment, and 4764 (13.6%) had no clinic blood pressure readings in the preceding 5 years from the data extraction date. Of the remaining 20 255 patients (57.9%), 4985 (14.3%) had total and HDL cholesterol information available to calculate CVD risk, leaving 15 270 (43.7%) where cholesterol was imputed. Diabetes, chronic kidney disease, and ischaemic heart disease were the most common comorbidities (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><p>Characteristics of the study population, <italic>n</italic> = 34 975</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1"><bold>Characteristic</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold><italic>n</italic> (%)<xref ref-type="table-fn" rid="tfn6"><sup>a</sup></xref></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">16990 (49)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x000b1; 10)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">South Asian ethnicity</td><td valign="top" align="center" rowspan="1" colspan="1">1899 (12)<xref ref-type="table-fn" rid="tfn7"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family history of CVD</td><td valign="top" align="center" rowspan="1" colspan="1">4213 (12)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes</td><td valign="top" align="center" rowspan="1" colspan="1">2598 (7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left ventricular hypertrophy</td><td valign="top" align="center" rowspan="1" colspan="1">77 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic kidney disease</td><td valign="top" align="center" rowspan="1" colspan="1">1302 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Myocardial infarction</td><td valign="top" align="center" rowspan="1" colspan="1">733 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Peripheral vascular disease</td><td valign="top" align="center" rowspan="1" colspan="1">487 (1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Heart failure</td><td valign="top" align="center" rowspan="1" colspan="1">253 (1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ischaemic heart disease</td><td valign="top" align="center" rowspan="1" colspan="1">1678 (5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stroke</td><td valign="top" align="center" rowspan="1" colspan="1">331 (1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Transient ischaemic attack</td><td valign="top" align="center" rowspan="1" colspan="1">295 (1)</td></tr></tbody></table><table-wrap-foot><fn id="tfn6"><label>a</label><p>Unless otherwise stated.</p></fn><fn id="tfn7"><label>b</label><p>Percentage of 15 825 patients in whom ethnicity was recorded. Ethnicity is typically collected by self-report at registration; the relatively low proportions recorded reflect patients who have been registered for some years. CVD = cardiovascular disease. SD = standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Prevalence of untreated, uncomplicated stage 1 hypertension</title><p>A total of 12 647 patients had hypertension, of which 4421 patients (35.0%) were not receiving antihypertensive treatment. In patients receiving no treatment, stage 1 hypertension was present in 3321 individuals (9.5%, 95% CI = 9.2 to 9.8), of whom 2867 (8.2%, 95% CI = 7.9 to 8.5) had low CVD risk (that is, &#x02018;uncomplicated&#x02019;). Untreated, uncomplicated stage 1 hypertension was more common in younger patients (1729 patients, 9.1%, 95% CI = 8.7 to 9.5 [40&#x02013;54 years] versus 1138 patients, 7.1%, 95% CI = 6.7 to 7.5 [55&#x02013;74 years], <italic>P</italic>&#x0003c;0.001) and females (1465 patients, 8.6%, 95% CI = 8.2 to 9.1 [females] versus 1402 patients, 7.8%, 95% CI 7.4 to 8.2 [males], <italic>P</italic>=0.005), reflecting an increased risk of CVD in older patients and males. <xref ref-type="fig" rid="fig1">Figure 1</xref> shows the prevalence of hypertension and risk by age and sex. CVD risk is well known to be higher in males and older people.<xref rid="b34" ref-type="bibr">34</xref></p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold><italic>Prevalence of hypertension by age and sex.</italic></bold></p><p><italic>Treated hypertension = patients prescribed antihypertensive therapy. Normotension =</italic> &#x0003c;<italic>140/90 mmHg. Untreated stage 1 hypertension = 140/90&#x02013;159/99 mmHg. Untreated stage 2&#x02013;3 hypertension = &#x02265;160/100 mmHg. Prevalence of stage 1 hypertension was adjusted by a factor of 0.56 to account for the 56% positive predictive value of clinic BP measurements. All patients with a clinic BP of &#x02265;160/100 mmHg were considered to have stage 2 hypertension due to uncertainty about whether repeated measurement would affect classification at higher BP levels. BP = blood pressure. CVD = cardiovascular disease.</italic></p></caption><graphic xlink:href="bjgpOct-2014-64-627-e641"/></fig><p>By applying these figures to national population estimates<xref rid="b27" ref-type="bibr">27</xref> for people aged 40&#x02013;74 years, 1 892 519 patients in England and Wales (approximately 1 in 12 people) were estimated to have untreated, uncomplicated stage 1 hypertension.</p></sec><sec><title>Cost of treating uncomplicated stage 1 hypertension</title><p>Based on the cost of a practice nurse measuring a patient&#x02019;s blood pressure and delivering hypertension management (<xref ref-type="table" rid="table2">Table 2</xref>), the total cost of treating uncomplicated stage 1 hypertension in the sample population studied here was estimated to be &#x000a3;160 129 per year (<xref ref-type="table" rid="table4">Table 4</xref>). Extrapolated to the national population of England and Wales, this figure rises to &#x000a3;106 million per year. If hypertension care was delivered by a GP, this figure would rise to &#x000a3;229 million per year (US$180&#x02013;389 million or &#x020ac;134&#x02013;289 million) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><p>Costs of treating uncomplicated stage 1 hypertension across the sample and population of England and Wales, according to the health professional delivering treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1"><bold>Population</bold></th><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1"><bold>Cost, &#x000a3;<xref ref-type="table-fn" rid="tfn8"><sup>a</sup></xref></bold></th></tr></thead><tbody><tr><td rowspan="5" valign="top" align="left" colspan="1">Sample population, patients aged 40&#x02013;74 years</td><td valign="top" align="left" rowspan="1" colspan="1">Total, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">34 975</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Untreated, uncomplicated stage 1 hypertension,<xref ref-type="table-fn" rid="tfn9"><sup>b</sup></xref>
<italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">2867</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by practice nurse<xref ref-type="table-fn" rid="tfn10"><sup>c</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">160 129</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by nurse specialist<xref ref-type="table-fn" rid="tfn10"><sup>c</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">228 125</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by GP<xref ref-type="table-fn" rid="tfn11"><sup>d</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">347 117</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td rowspan="5" valign="top" align="left" colspan="1">Population of England and Wales, patients aged 40&#x02013;74 years<xref ref-type="table-fn" rid="tfn12"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Total population, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">23 284 217</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Untreated, uncomplicated stage 1 hypertension,<xref ref-type="table-fn" rid="tfn9"><sup>b</sup></xref>
<italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">1 892 519</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by practice nurse<xref ref-type="table-fn" rid="tfn10"><sup>c</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">105 619 247</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by nurse specialist<xref ref-type="table-fn" rid="tfn10"><sup>c</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">150 500 331</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cost of treatment if delivered by GP<xref ref-type="table-fn" rid="tfn11"><sup>d</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">229 042 227</td></tr></tbody></table><table-wrap-foot><fn id="tfn8"><label>a</label><p>Unless otherwise stated.</p></fn><fn id="tfn9"><label>b</label><p>Excludes patients with these conditions for whom blood pressure was not measured within 5 years prior to the study being undertaken.</p></fn><fn id="tfn10"><label>c</label><p>Nurse appointment based on 15-minute consultation.</p></fn><fn id="tfn11"><label>d</label><p>GP appointment based on 11.7-minute consultation.</p></fn><fn id="tfn12"><label>e</label><p><italic>Population in England and Wales is based on data from the Office for National Statistics, mid-year population estimates (2011).<xref rid="b27" ref-type="bibr">27</xref> Drug costs from</italic> NHS Electronic Drug Tariff <italic>database, correct as of May 2013.<xref rid="b28" ref-type="bibr">28</xref> Staff costs from</italic> Unit Costs of Health and Social Care 2012<italic>; unit costs based on the cost of face-to-face contact.<xref rid="b29" ref-type="bibr">29</xref></italic></p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec sec-type="conclusions"><title>Summary</title><p>This study shows that untreated, uncomplicated stage 1 hypertension is relatively common, affecting 1 in 12 patients aged between 40&#x02013;74 years in England and Wales. Assuming similar prevalence nationally, it was estimated that approximately 1.9 million people would be affected, with potential annual costs of antihypertensive treatment, if commenced, being &#x000a3;106&#x02013;229 million (US$180&#x02013;389million and &#x020ac;134&#x02013;289 million).</p><p>Initiation of therapy in such patients is not recommended (by guidelines) in the UK but many international guidelines do recommend therapy in this group,<xref rid="b3" ref-type="bibr">3</xref>&#x02013;<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b13" ref-type="bibr">13</xref> despite little evidence to suggest it has any benefit.<xref rid="b18" ref-type="bibr">18</xref> This study highlights that people with low risk stage 1 hypertension form a significant group for whom more robust evidence of cost-effectiveness is needed prior to commencement of antihypertensive treatment.</p></sec><sec><title>Strengths and limitations</title><p>This study used routine data from the West Midlands, UK, and included all registered patients aged 40&#x02013;74 years from a large cohort of general practices. These data were comparable with the national population aged 35&#x02013;74 years, in terms of mean age and sex,<xref rid="b27" ref-type="bibr">27</xref> prevalence of stroke and ischaemic heart disease, diabetes, untreated hypertension,<xref rid="b22" ref-type="bibr">22</xref> and mortality.<xref rid="b39" ref-type="bibr">39</xref> It was not possible to compare the characteristics of the study population with national trends in ethnicity and social deprivation, and it is acknowledged that results extrapolated from local to national population data should be interpreted with caution.</p><p>Data used here were collected in 2008 and 2009 but the researchers are confident that the prevalence estimates are still relevant today. According to figures from the Quality and Outcomes Framework (QOF),<xref rid="b19" ref-type="bibr">19</xref> the prevalence of diagnosed hypertension in England has increased very slightly in the past 5 years (0.3%; from 13.4% to 13.7%). The researchers would not anticipate treatment to have changed very much during this period, given that QOF targets have remained largely the same. Although NICE now recommends the use of ambulatory blood pressure monitoring in the diagnosis of hypertension,<xref rid="b12" ref-type="bibr">12</xref> this was not expected to greatly influence the present results as prevalence estimates were adjusted to account for the accuracy (and variability) of clinic blood pressure used in isolation.<xref rid="b33" ref-type="bibr">33</xref></p><p>The estimates of the prevalence of untreated, uncomplicated stage 1 hypertension presented here may be conservative: patients without a blood pressure reading in the 5 years prior to the study were assumed to not have stage 1 hypertension. Where it was recorded, no correction was made for blood pressure measurement error in patients with stage 2&#x02013;3 hypertension due to uncertainty about the PPV of readings taken around the 160/100 mmHg threshold. In practice, there is likely to be a degree of measurement error, resulting in some patients with stage 1 hypertension being classed as having stage 2&#x02013;3 hypertension and vice versa. The Framingham equation may overestimate risk, resulting in the misclassification of individuals (as high risk) and reducing our estimate of the prevalence of uncomplicated stage 1 hypertension;<xref rid="b40" ref-type="bibr">40</xref> however, this tool was recommended for use in clinical practice by NICE at the time of data collection.<xref rid="b35" ref-type="bibr">35</xref></p><p>The assessments of CVD risk undertaken were limited to evaluating existing CVD and CVD risk score; target organ damage, and diabetes were not considered separately, although the latter was included in the Framingham risk equation used here.<xref rid="b34" ref-type="bibr">34</xref> Therefore, it is possible that a minority of patients may have been classified as low risk when, in practice, most would be treated as high risk. In the case of diabetes, however, only 211 patients were classified as low risk (1.0%), so the impact of any misclassification is likely to be relatively small. In addition, CVD risk was calculated using cholesterol readings, which were imputed in 15 270 patients. This represents a large proportion of the overall sample (44%) and there remains the possibility that such an approach may have affected the accuracy of risk estimates and, as such, also the overall estimates of untreated, uncomplicated stage 1 hypertension.</p><p>Finally, an assumption was made that there are no long-term benefits from the treatment of uncomplicated stage 1 hypertension, in terms of potential cost savings based on the Cochrane Review findings.<xref rid="b18" ref-type="bibr">18</xref> Should this assumption be incorrect, these results will underestimate potential benefit.</p></sec><sec><title>Comparison with existing literature</title><p>To the authors&#x02019; knowledge, this is the first study to document the community prevalence of untreated, uncomplicated stage 1 hypertension anywhere in the world. The prevalence of hypertension in international surveys varies by method of diagnosis, and between countries and continents, from 23.0% to 46.0%<xref rid="b20" ref-type="bibr">20</xref>&#x02013;<xref rid="b24" ref-type="bibr">24</xref>,<xref rid="b41" ref-type="bibr">41</xref> (depending on the age range of the population studied); the lowest rates have been reported in Canada<xref rid="b20" ref-type="bibr">20</xref> and the highest across Africa.<xref rid="b23" ref-type="bibr">23</xref> Estimates of untreated hypertension (12.6%) were comparable with those from previous surveys conducted in Australia (13.1%),<xref rid="b24" ref-type="bibr">24</xref> England (15.8%),<xref rid="b22" ref-type="bibr">22</xref> and Japan (15.9%).<xref rid="b26" ref-type="bibr">26</xref></p></sec><sec sec-type="discussion"><title>Implications for research and practice</title><p>This study found that 1 in 12 patients aged 40&#x02013;74 years have untreated, uncomplicated stage 1 hypertension. The cost of a strategy to treat these patients in clinical practice was estimated to fall between &#x000a3;106 million and &#x000a3;229 million (US$180&#x02013;389 million or &#x020ac;134&#x02013;289 million). Whether to initiate treatment in patients with uncomplicated stage 1 hypertension is a source of much debate.<xref rid="b14" ref-type="bibr">14</xref>&#x02013;<xref rid="b17" ref-type="bibr">17</xref> The recent Cochrane Review by Diao <italic>et al</italic>,<xref rid="b18" ref-type="bibr">18</xref> found no evidence that antihypertensive treatment in this population would result in reductions in mortality, coronary artery disease, stroke, or total CVD. Although both the authors of that review and subsequent commentators<xref rid="b15" ref-type="bibr">15</xref> point to a lack of power to show benefit, estimates of a number needed to treat (NNT) of 128 for 5 years per cardiovascular event averted suggest few people stand to gain from such treatment.<xref rid="b18" ref-type="bibr">18</xref> Indeed, one previous study<xref rid="b42" ref-type="bibr">42</xref> suggested that patients judge the maximum acceptable NNT for 5 years to prevent one death in hypertension to be 33 &#x02014; well below the putative NNT for CVD &#x02014; rather than mortality benefit from treating uncomplicated stage 1 hypertension.</p><p>Since the publication of the Cochrane Review,<xref rid="b18" ref-type="bibr">18</xref> three guidelines for the management of hypertension have been published:
<list list-type="bullet"><list-item><p>The Canadian Hypertension Education Program guidelines<xref rid="b4" ref-type="bibr">4</xref> discounted the findings of the Cochrane Review because of the small sample size and cited a 35-year-old non-placebo trial<xref rid="b43" ref-type="bibr">43</xref> as justification for maintaining the recommendation to treat uncomplicated stage 1 hypertension (with the caveat that lifestyle modification may be sufficient to control blood pressure without the initiation of therapy).<xref rid="b4" ref-type="bibr">4</xref></p></list-item><list-item><p>The European Society of Hypertension (ESH) guidelines<xref rid="b3" ref-type="bibr">3</xref> also note the lack of power in the Cochrane Review<xref rid="b18" ref-type="bibr">18</xref> and highlight the paucity of evidence to guide therapy. However, taking into account the limited available evidence<xref rid="b44" ref-type="bibr">44</xref> and the low cost and safety of antihypertensive agents, ESH recommends considering blood pressure-lowering therapy in this population.</p></list-item><list-item><p>The Eighth Joint National Committee guidelines<xref rid="b13" ref-type="bibr">13</xref> revised thresholds for treatment such that patients aged &#x02265;60 years should be given treatment if their blood pressure is &#x02265;150/90 mmHg. In patients aged &#x0003c;60 years, initiation of treatment was encouraged at a threshold of 140/90 mmHg (regardless of risk), although it was acknowledged that this recommendation was based on expert opinion alone.</p></list-item></list></p><p>The data presented here do not suggest that therapy to reduce blood pressure in those with low CVD risk and stage 1 hypertension would provide an adequate cost&#x02013;benefit ratio, given the high NNT and costs in order to prevent one vascular event, along with the potential adverse consequences an individual may experience having been labelled as having hypertension through side effects and labelling.<xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b45" ref-type="bibr">45</xref>,<xref rid="b46" ref-type="bibr">46</xref></p><p>Untreated, uncomplicated stage 1 hypertension is common, affecting at least 8.2% of the population aged 40&#x02013;74 years in England and Wales. International guidelines<xref rid="b3" ref-type="bibr">3</xref>&#x02013;<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b13" ref-type="bibr">13</xref> and pay-for-performance targets<xref rid="b19" ref-type="bibr">19</xref> encouraging universal thresholds and treatment targets of &#x0003c;140/90 mmHg (regardless of underlying CVD risk) will lead to treatment, with little prospect of benefit at substantial financial cost to healthcare providers across the world. International recommendations should be re-examined to ensure evidence-based treatment until such time as new trials show that benefit outweighs harm and is cost effective.</p></sec></sec></body><back><ack><p>We thank all of the general practices for their participation and cooperation with this study. All authors had full access to all of the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis.</p></ack><notes><sec><title>Funding</title><p>This work forms part of a larger programme on stroke prevention in primary care supported by the National Institute for Health Research (NIHR) (RP-PG-0606-1153). James P Sheppard holds a Medical Research Council Strategic Skills PostDoctoral Fellowship. Richard J McManus holds an NIHR Professorship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NHS, NIHR, or the Department of Health.</p></sec><sec><title>Ethical approval</title><p>All data collection was approved by the Birmingham East, North and Solihull Research Ethics Committee in June 2008 (reference number: 08/H1206/91).</p></sec><sec><title>Provenance</title><p>Freely submitted; externally peer reviewed.</p></sec><sec><title>Competing interests</title><p>The authors have declared no competing interests.</p></sec><sec><title>Discuss this article</title><p>Contribute and read comments about this article: <bold><ext-link ext-link-type="uri" xlink:href="www.bjgp.org/letters">www.bjgp.org/letters</ext-link></bold></p></sec></notes><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewington</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Qizilbash</surname><given-names>N</given-names></name><etal/></person-group><article-title>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1903</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">12493255</pub-id></element-citation></ref><ref id="b2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selected major risk factors and global and regional burden of disease</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1347</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">12423980</pub-id></element-citation></ref><ref id="b3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><etal/></person-group><article-title>2013 ESH/ESC practice guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>28</issue><fpage>2159</fpage><lpage>2219</lpage><pub-id pub-id-type="pmid">23771844</pub-id></element-citation></ref><ref id="b4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackam</surname><given-names>DG</given-names></name><name><surname>Quinn</surname><given-names>RR</given-names></name><name><surname>Ravani</surname><given-names>P</given-names></name><etal/></person-group><article-title>The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension</article-title><source>Can J Cardiol</source><year>2013</year><volume>29</volume><issue>5</issue><fpage>528</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">23541660</pub-id></element-citation></ref><ref id="b5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>LB</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Alberts</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline</article-title><source>Stroke</source><year>2006</year><volume>37</volume><issue>6</issue><fpage>1583</fpage><lpage>1633</lpage><pub-id pub-id-type="pmid">16675728</pub-id></element-citation></ref><ref id="b6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosendorff</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>21</issue><fpage>2761</fpage><lpage>2788</lpage><pub-id pub-id-type="pmid">17502569</pub-id></element-citation></ref><ref id="b7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>RA</given-names></name><name><surname>Ayala</surname><given-names>M</given-names></name><name><surname>Baglivo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Latin American guidelines on hypertension. Latin American Expert Group</article-title><source>J Hypertens</source><year>2009</year><volume>27</volume><issue>5</issue><fpage>905</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">19349909</pub-id></element-citation></ref><ref id="b8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitworth</surname><given-names>JA</given-names></name></person-group><article-title>2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension</article-title><source>J Hypertens</source><year>2003</year><volume>21</volume><issue>11</issue><fpage>1983</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">14597836</pub-id></element-citation></ref><ref id="b9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name><etal/></person-group><article-title>The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)</article-title><source>Hypertens Res</source><year>2009</year><volume>32</volume><issue>1</issue><fpage>3</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">19300436</pub-id></element-citation></ref><ref id="b10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>New Zealand Guidelines Group</collab></person-group><source>The Assessment and Management of Cardiovascular Risk</source><year>2003</year><publisher-loc>Wellington</publisher-loc><publisher-name>New Zealand Guidelines Group</publisher-name></element-citation></ref><ref id="b11"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee)</collab></person-group><source>Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults</source><comment>Updated December 2010<ext-link ext-link-type="uri" xlink:href="http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf">http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf</ext-link> (accsessed 27 Jul 2014)</comment></element-citation></ref><ref id="b12"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Care excellence</collab></person-group><source>hypertension: Clinical Management of Primary Hypertension in Adults</source><year>2011</year><comment>Report No: CG127. <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/CG127">http://www.nice.org.uk/CG127</ext-link> (accessd 27 Jul 2014)</comment></element-citation></ref><ref id="b13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>PA</given-names></name><name><surname>Oparil</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>BL</given-names></name><etal/></person-group><article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>5</issue><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">24352797</pub-id></element-citation></ref><ref id="b14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heath</surname><given-names>I</given-names></name></person-group><article-title>Waste and harm in the treatment of mild hypertension</article-title><source>JAMA Intern Med</source><year>2013</year><volume>173</volume><issue>11</issue><fpage>956</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">23699902</pub-id></element-citation></ref><ref id="b15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenzer</surname><given-names>J</given-names></name></person-group><article-title>Cochrane review finds no proved benefit in drug treatment for patients with mild hypertension</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e5511</fpage><pub-id pub-id-type="pmid">22893663</pub-id></element-citation></ref><ref id="b16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>LE</given-names></name><name><surname>ul Haq</surname><given-names>I</given-names></name><name><surname>Yeo</surname><given-names>WW</given-names></name><name><surname>Jackson</surname><given-names>PR</given-names></name></person-group><article-title>Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?</article-title><source>J Hypertens Suppl</source><year>1996</year><volume>14</volume><issue>5</issue><fpage>S187</fpage><lpage>S194</lpage><pub-id pub-id-type="pmid">9120677</pub-id></element-citation></ref><ref id="b17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>PJ</given-names></name><name><surname>Horwitz</surname><given-names>RI</given-names></name></person-group><article-title>Conflicting clinical trials and the uncertainty of treating mild hypertension</article-title><source>Am J Med</source><year>1983</year><volume>75</volume><issue>3</issue><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">6351610</pub-id></element-citation></ref><ref id="b18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>D</given-names></name><name><surname>Wright</surname><given-names>JM</given-names></name><name><surname>Cundiff</surname><given-names>DK</given-names></name><name><surname>Gueyffier</surname><given-names>F</given-names></name></person-group><article-title>Pharmacotherapy for mild hypertension</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>8</volume><fpage>CD006742</fpage><pub-id pub-id-type="pmid">22895954</pub-id></element-citation></ref><ref id="b19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>NHS Employers, General Practitioners Committee, NHS England</collab></person-group><source>2013/14 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF): guidence for GMS contract 2013/14</source><year>2013</year><publisher-loc>Leeds</publisher-loc><publisher-name>NHS Employers</publisher-name></element-citation></ref><ref id="b20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robitaille</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>C</given-names></name><etal/></person-group><article-title>Diagnosed hypertension in Canada: incidence, prevalence and associated mortality</article-title><source>CMAJ</source><year>2012</year><volume>184</volume><issue>1</issue><fpage>e49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">22105752</pub-id></element-citation></ref><ref id="b21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olives</surname><given-names>C</given-names></name><name><surname>Myerson</surname><given-names>R</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Prevalence, awareness, treatment, and control of hypertension in United States counties, 2001&#x02013;2009</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>4</issue><fpage>e60308</fpage><pub-id pub-id-type="pmid">23577099</pub-id></element-citation></ref><ref id="b22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boniface</surname><given-names>S</given-names></name><name><surname>Bridges</surname><given-names>S</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name><etal/></person-group><source>Health survey for England 2011: volume 1 &#x02014; health, social care and lifestyles</source><comment><ext-link ext-link-type="uri" xlink:href="http://www.hscic.gov.uk/catalogue/PUB09300/HSE2011-Ch1-Intro.pdf">http://www.hscic.gov.uk/catalogue/PUB09300/HSE2011-Ch1-Intro.pdf</ext-link> (accessed 27 Jul 2014)</comment></element-citation></ref><ref id="b23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Global Status Report on Noncommunicable Diseases 2010: description of the global burden of NCDs, their risk factors and determinants</source><year>2011</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/nmh/publications/ncd_report2010/en/">http://www.who.int/nmh/publications/ncd_report2010/en/</ext-link> (accessed 27 Jul 2014)</comment></element-citation></ref><ref id="b24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appleton</surname><given-names>SL</given-names></name><name><surname>Neo</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Untreated hypertension: prevalence and patient factors and beliefs associated with under-treatment in a population sample</article-title><source>J Hum Hypertens</source><year>2013</year><volume>27</volume><issue>7</issue><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">23235365</pub-id></element-citation></ref><ref id="b25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Prevalence, awareness, treatment, and control of hypertension in China</article-title><source>Hypertension</source><year>2002</year><volume>40</volume><issue>6</issue><fpage>920</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">12468580</pub-id></element-citation></ref><ref id="b26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Treated and untreated hypertension, hospitalization, and medical expenditure: an epidemiological study in 314 622 beneficiaries of the medical insurance system in Japan</article-title><source>J Hypertens</source><year>2013</year><volume>31</volume><issue>5</issue><fpage>1032</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">23449017</pub-id></element-citation></ref><ref id="b27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Office for National Statistics</collab></person-group><source>Annual mid-year population estimates for England and Wales, Mid 2011</source><year>2012</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.ons.gov.uk/ons/dcp171778_277794.pdf">http://www.ons.gov.uk/ons/dcp171778_277794.pdf</ext-link> (accessed 27 Jul 2014)</comment></element-citation></ref><ref id="b28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>NHS Prescription Services</collab></person-group><source>NHS electronic drug tariff</source><year>2013</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.ppa.org.uk/edt/May_2013/mindex.htm">http://www.ppa.org.uk/edt/May_2013/mindex.htm</ext-link> (accessed 9 Sep 2014)</comment></element-citation></ref><ref id="b29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>L</given-names></name></person-group><source>Unit costs of health and social care 2012</source><comment><ext-link ext-link-type="uri" xlink:href="http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-covers.pdf">http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-covers.pdf</ext-link> (accessed 27 Jul 2014)</comment></element-citation></ref><ref id="b30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>JP</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Fletcher</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e4535</fpage><pub-id pub-id-type="pmid">22791787</pub-id></element-citation></ref><ref id="b31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>JP</given-names></name><name><surname>Fletcher</surname><given-names>K</given-names></name><name><surname>McManus</surname><given-names>RJ</given-names></name><name><surname>Mant</surname><given-names>J</given-names></name></person-group><article-title>Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study</article-title><source>Br J Gen Pract</source><year>2014</year><pub-id pub-id-type="doi">10.3399/bjgp14X676447</pub-id></element-citation></ref><ref id="b32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wierzbicki</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Banks</surname><given-names>L</given-names></name><etal/></person-group><source>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</source><year>2014</year><comment>NICE guidelines (CG181). <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/Guidance/CG181">http://www.nice.org.uk/Guidance/CG181</ext-link> (accessed 9 Sep 2014)</comment></element-citation></ref><ref id="b33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkinson</surname><given-names>J</given-names></name><name><surname>Mant</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>U</given-names></name><etal/></person-group><article-title>Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review</article-title><source>BMJ</source><year>2011</year><volume>342</volume><fpage>d3621</fpage><pub-id pub-id-type="pmid">21705406</pub-id></element-citation></ref><ref id="b34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Odell</surname><given-names>PM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Cardiovascular disease risk profiles</article-title><source>Am Heart J</source><year>1991</year><volume>121</volume><issue>1 Pt 2</issue><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">1985385</pub-id></element-citation></ref><ref id="b35"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Clinical Excellence</collab></person-group><source>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</source><year>2008</year><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name><comment>Report No: CG067</comment></element-citation></ref><ref id="b36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hippisley-Cox</surname><given-names>J</given-names></name><name><surname>Coupland</surname><given-names>C</given-names></name><name><surname>Vinogradova</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>1475</fpage><lpage>1482</lpage><pub-id pub-id-type="pmid">18573856</pub-id></element-citation></ref><ref id="b37"><label>37.</label><element-citation publication-type="journal"><article-title>National Institute for Health and Care Excellence</article-title><source>Assessing cost impact: methods guide</source><year>2011</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/Costing_Manual_update_050811.pdf">http://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/Costing_Manual_update_050811.pdf</ext-link> (accessed 27 Jul 2014)</comment></element-citation></ref><ref id="b38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Carruthers</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1755</fpage><lpage>1762</lpage><pub-id pub-id-type="pmid">9635947</pub-id></element-citation></ref><ref id="b39"><label>39.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Office for National Statistics</collab></person-group><source>Mortality statistics: deaths registered in England &#x00026; Wales</source><year>2010</year><comment>Series DR. 10-5-2012<ext-link ext-link-type="uri" xlink:href="http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-230730">http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-230730</ext-link> (accessed 9 Sep 2014)</comment></element-citation></ref><ref id="b40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuhauser</surname><given-names>HK</given-names></name><name><surname>Ellert</surname><given-names>U</given-names></name><name><surname>Kurth</surname><given-names>BM</given-names></name></person-group><article-title>A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2005</year><volume>12</volume><issue>5</issue><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">16210930</pub-id></element-citation></ref><ref id="b41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Whelton</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><etal/></person-group><article-title>Global burden of hypertension: analysis of worldwide data</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">15652604</pub-id></element-citation></ref><ref id="b42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>N</given-names></name></person-group><article-title>Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey</article-title><source>BMJ</source><year>2000</year><volume>320</volume><fpage>1446</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">10827049</pub-id></element-citation></ref><ref id="b43"><label>43.</label><element-citation publication-type="journal"><article-title>Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group</article-title><source>JAMA</source><year>1979</year><volume>242</volume><issue>23</issue><fpage>2562</fpage><lpage>2571</lpage><comment>[No authors listed].</comment><pub-id pub-id-type="pmid">490882</pub-id></element-citation></ref><ref id="b44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Is a systolic blood pressure target &#x0003c;140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>12</issue><fpage>1500</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">21345850</pub-id></element-citation></ref><ref id="b45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Batty</surname><given-names>GD</given-names></name><name><surname>Stamatakis</surname><given-names>E</given-names></name><name><surname>Kivimaki</surname><given-names>M</given-names></name></person-group><article-title>Hypertension awareness and psychological distress</article-title><source>Hypertension</source><year>2010</year><volume>56</volume><issue>3</issue><fpage>547</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">20625078</pub-id></element-citation></ref><ref id="b46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickering</surname><given-names>TG</given-names></name></person-group><article-title>Now we are sick: labeling and hypertension</article-title><source>J Clin Hypertens (Greenwich)</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16407691</pub-id></element-citation></ref></ref-list></back></article>